Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RPR

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  Next»
    Study title: Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone.
    Active substance: BENZATROPINE
    Study summary document link (including results):
    View full study record
    Document reference: 22243
    Study title: Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone.
    Active substance: BENZATROPINE
    Study summary document link (including results):
    View full study record
    Document reference: 41947
    Study title: A Comparative Study of Single-Dose Intramuscular (IM) Ceftriaxone and a 10-Day Oral (PO) Course of Trimethorprim-sulfamethoxazole for the Treatment of Acute Otitis Media in Infants and Children
    Active substance: CEFTRIAXONE
    Study summary document link (including results):
    View full study record
    Document reference: 23622
    Study title: How to interpret a deterioration of split function?Piepsz A, Ismaili K, Hall M, Collier F, Tondeur M, Ham H.Eur Urol. 2005 May;47(5):686-90. Epub 2005 Jan 11.
    Active substance: CHROMIUM 51
    Study summary document link (including results): Piepsz A et al 2005b.pdf
    View full study record
    Document reference: 24090
    Study title: Lachapelle JM et al. Itraconazole compared with griseofulvin in the treatment of Tinea corporis/cruris and Tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 184:45, 1992. (6-58 years, LMD81740)Lachapelle JM et al. Itraconazole compared with griseofulvin in the treatment of Tinea corporis/cruris and Tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 184:45, 1992. (6-58 years, LMD81740)
    Active substance: ITRACONAZOLE
    Study summary document link (including results):
    View full study record
    Document reference: 30780
    Study title: Rockland L, et al. Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics. Can J Psychiatry 1990 Oct; 35(7): 604-7. Erratum Can J Psychiatry 1991 Feb;36(1):73Rockland L, et al. Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics. Can J Psychiatry 1990 Oct; 35(7): 604-7. Erratum Can J Psychiatry 1991 Feb;36(1):73
    Active substance: TRIHEXYPHENIDYL
    Study summary document link (including results):
    View full study record
    Document reference: 46742
    Study title: Nucl Med Commun. 2007 Apr;28(4):273-80.Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B.
    Active substance: FLUDEOXYGLUCOSE
    Study summary document link (including results):
    View full study record
    Document reference: 28068
    Study title: A randomised double blind nultiple-dose study comparing the efficacy and tolerability of Iburprofen versus Paracetamol (both syrup formulations) in the treatment of fever in children known with febrile convulsions
    Active substance: IBUPROFEN
    Study summary document link (including results): ibuprofen- br1178-vanEsch.xls
    View full study record
    Document reference: 29414
    Study title: Bleckmann K.H. Erfahrungsbericht über die Anwendung von Pyrithioxin in der Kinderpraxis (Praxis der Kinderpsychologie und Kinderpsychiatrie 1965; 14(8): 316-7); Bleckmann K.H. Erfahrungsbericht über die Anwendung von Pyrithioxin in der Kinderpraxis (Praxis der Kinderpsychologie und Kinderpsychiatrie 1965; 14(8): 316-7);
    Active substance: PSEUDOEPHEDRINE/ PSEUDOEPHEDRINE AND TRIPTOLIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 35150
    Study title: J Nucl Med. 2004 Apr;45(4):559-66. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. SchÃder H, Erdi YE, Chao K, Gonen M, Larson SM, Yeung HW.
    Active substance: FLUDEOXYGLUCOSE
    Study summary document link (including results):
    View full study record
    Document reference: 28128
    Study title: Anwendungsbeobachtung zur Überprüfung der Wirksamkeit und Verträglichkeit von Leukichtan N 10 % Gel bei Patienten mit Schnittwunden, Schürfwunden oder Verbrennungen
    Active substance: GADOTERIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28877
    Study title: Überprüfung der Wirksamkeit und Verträglichkeit von Ichthocortin® Gel und Elidel® 1% Creme bei Kindern mit leichter bis mittelschwerer atopischer Dermatitis
    Active substance: ICHTASOL
    Study summary document link (including results):
    View full study record
    Document reference: 29758
    Study title: Pre-pubertal growth in the hyperprostaglandin E syndrome.
    Active substance: INDOMETHACIN
    Study summary document link (including results):
    View full study record
    Document reference: 29989
    Study title: Effects of dextroamphetamine, chlorpromazine, and hydroxy- zine on behavior and performance in hyperactive children
    Active substance: HYDROXYZINE
    Study summary document link (including results): ADPE92B1901.pdf
    View full study record
    Document reference: 29266
    Study title: Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.
    Active substance: INDOMETHACIN
    Study summary document link (including results):
    View full study record
    Document reference: 29826
    Study title: Überprüfung der Wirksamkeit und Verträglichkeit einer Milchschorf Creme bei Säuglingen und Kleinkindern bis zum vollendeten 2. Lebensjahr
    Active substance: ICHTASOL
    Study summary document link (including results):
    View full study record
    Document reference: 29759
    Study title: Überprüfung der Wirksamkeit und Verträglichkeit einer Neurodermitis Creme bei Säuglingen und Kindern bis zum vollendeten 6. Lebensjahr
    Active substance: ICHTASOL
    Study summary document link (including results):
    View full study record
    Document reference: 29766
    Study title: Jarman underproveleged area scores, tooth decay and the effect of water fluoridation1997-jones
    Active substance: SODIUM FLUORIDE
    Study summary document link (including results): 1997-jones-Jarman underproveleged area scores, tooth decay and the effect of water fluoridation.pdf
    View full study record
    Document reference: 49123
    Study title: Clinical Implications of Different Image Reconstruction Parameters for Interpretation of Whole-Body PET Studies in Cancer Patients.J Nucl Med 2004; 45:559–566. Heiko Scho¨der, MD1; Yusuf E. Erdi, DSc2; Kenneth Chao, BS1; Mithat Gonen, PhD3; Steven M. Larson, MD1; and Henry W.D. Yeung, MD1.
    Active substance: Steripet
    Study summary document link (including results): schulte-1999.pdf
    View full study record
    Document reference: 48746
    Study title: Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B.. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. [falk-2007]Nucl Med Commun. 2007 Apr;28(4):273-80. Falk MS 2007
    Active substance: Steripet
    Study summary document link (including results): 2011-09 GE response Template List of published articles.doc
    View full study record
    Document reference: 48643
    1  2  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 19:33:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA